Uptravi 600 mcg (Selexipag TABLET) 600 MCG

UPTRAVI 600 MCG tablets contain the active ingredient selexipag, used for managing certain cardiovascular conditions. This medication is designed to support heart health and improve circulation.

Strength

600 MCG

Pack Size

Manufacturer / TM Owner

JANSSEN INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

UPTRAVI 600 MCG tablets are primarily used to treat conditions related to pulmonary arterial hypertension. Selexipag works by relaxing blood vessels, which can help reduce the workload on the heart and improve blood flow. This medication is often prescribed as part of a comprehensive treatment plan for managing symptoms associated with cardiovascular health.

Side Effects

Common effects of UPTRAVI 600 MCG tablets may include headaches, nausea, and dizziness. Some users might also experience diarrhea or fatigue. These effects can vary from person to person and may subside as the body adjusts to the medication.

Precautions & Warnings

UPTRAVI 600 MCG tablets should be handled with care. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Keep the medication out of reach of children and store it at room temperature unless otherwise directed.

Avoid Interactions

UPTRAVI 600 MCG tablets may interact with certain medications, including those metabolized by the liver's CYP enzymes. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol consumption should also be discussed with a healthcare professional.

References

Frequently Asked Questions

UPTRAVI 600 MCG tablets are used to manage symptoms associated with pulmonary arterial hypertension by improving blood flow and reducing the workload on the heart.

UPTRAVI 600 MCG tablets are taken orally, typically once or twice daily. Follow the specific instructions provided by your healthcare professional.

Common side effects may include headaches, nausea, dizziness, diarrhea, and fatigue. These effects can vary and may subside over time.

It is important to discuss alcohol consumption with your healthcare provider, as it may interact with UPTRAVI 600 MCG tablets.

Store UPTRAVI 600 MCG tablets at room temperature, away from moisture and heat, and keep them out of reach of children.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.